• 5 May 2011

    Endosense and BIOTRONIK SE & Co. KG have announced that Endosense’s TactiCath1 contact-force sensing ablation catheter has been used to perform more than one thousand patient cases of atrial fibrillation (AF) in Europe within the last twelve months. The commercial milestone, which coincided with the companies’ presence at the Heart Rhythm Society’s 32nd Annual Scientific Sessions in San Francisco, marks a significant achievement for both organizations. Endosense pioneered the field of contact-force sensing in catheter ablation with the development of its TactiCath catheter and accompanying Tactisys system, the second generation of which were launched in April 2010. BIOTRONIK has built and is continuing to grow the market for the TactiCath as its exclusive distributor in Europe as well as Latin America, Canada, Africa and the Middle East.

  • 4 May 2011

    Rhythmia Medical Inc. and Endosense have engaged in a joint development project to integrate the contact-force data provided by Endosense’s TactiCath® force-sensing ablation catheter1 into Rhythmia’s advanced three-dimensional cardiac mapping, visualization and navigation system. The project’s objective is to build on earlier feasibility tests to develop an integrated solution that allows electrophysiologists to quickly, efficiently and effectively view catheter tip-to-tissue contact force on a high-resolution, 3-D electro-anatomical map.

  • 26 April 2011

    Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that KUR-113 (Viz. I-040202) met the primary efficacy endpoint in a 200 patient Phase IIb clinical trial designed to assess its efficacy and safety in open tibial shaft fracture patients. The primary endpoint of the study is the proportion of patients healed at 6 months after surgery, comparing KUR-113 in combination with standard of care (SOC) to SOC alone. The use of KUR-113 is designed to improve fracture union and thus reduce the time needed to achieve bone healing as well as the incidence of secondary interventions.

  • 26 April 2011

    Kuros Biosurgery AG, a company focused on the development of novel biomaterials and bioactive-biomaterials combinatino products for trama, wound and spinal indications, announced today that it has regained rights to a number of trauma and spine product candidates that were previously licensed to Baxter International Inc.

  • 10 March 2011

    Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results from its Phase IIa study of its lead product CT327 in psoriasis vulgaris.